The Technical Analyst
C4 Therapeutics, Inc. [CCCC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
C4 Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.75% $6.72
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 461.00 mill |
| EPS: | -2.67 |
| P/E: | -2.52 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 68.60 mill |
| Avg Daily Volume: | 2.70 mill |
| RATING 2024-04-19 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.52 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.43x |
| Company: PE -2.52 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.180 (-117.55%) $-7.90 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.04 - 7.41 ( +/- 10.19%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-14 | Mossler Mark | Buy | 27 430 | Stock Option (Right to Buy) |
| 2024-02-14 | Mossler Mark | Buy | 18 290 | Common Stock |
| 2024-04-01 | Anderson Kenneth Carl | Buy | 1 389 | Common Stock |
| 2024-04-01 | Dubin Glenn | Buy | 1 358 | Common Stock |
| 2024-04-01 | Grogan Donna Roy | Buy | 1 697 | Common Stock |
| INSIDER POWER |
|---|
| 59.75 |
| Last 98 transactions |
| Buy: 4 435 645 | Sell: 1 001 966 |
Forecast:
16:00 - $6.75
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.75
Forecast 2: 16:00 - $6.75
Forecast 3: 16:00 - $6.75
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.72 (-2.75% ) |
| Volume | 1.705 mill |
| Avg. Vol. | 2.70 mill |
| % of Avg. Vol | 63.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CCCC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $5.63 | N/A | Active |
|---|
CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-09 07:00:00 - Press Release
C4 Therapeutics To Participate In The Stifel 2024 Targeted Oncology Forum
Watertown, mass., april 09, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that c4t management will participate in a fireside chat at the stifel 2024 targeted oncology forum taking place virtually from april 16 – april 17, 2024.
2024-04-08 08:00:00 - Press Release
C4 Therapeutics Presents New Preclinical Data For Cft1946 Highlighting Superior Activity As A Single Agent To Clinically Approved Braf Inhibitor Standard Of Care Combinations At The American Association For Cancer Research Annual Meeting 2024
Watertown, mass., april 08, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the american association for cancer research (aacr) annual meeting 2024 highlighting new preclinical data for cft1946 across multiple models of braf v600x mutant colorectal cancer (crc) and non-small cell lung cancer (nsclc), additional braf inhibitor (brafi)-resistant melanoma models, and an intracranial model of braf v600e metastatic melanoma.
2024-03-05 16:30:00 - Press Release
C4 Therapeutics To Present New Preclinical Data On Highly Selective Orally Bioavailable Bidac™ Degraders At The American Association For Cancer Research Annual Meeting 2024
Cft1946 data demonstrates promising single agent and combination activity in preclinical models of braf v600x melanoma, colorectal cancer, non-small cell lung cancer and brain metastasis cft1946 data demonstrates promising single agent and combination activity in preclinical models of braf v600x melanoma, colorectal cancer, non-small cell lung cancer and brain metastasis
2024-03-04 07:00:00 - Press Release
C4 Therapeutics Announces Strategic Discovery Research Collaboration With Merck Kgaa, Darmstadt, Germany, Against Critical Oncogenic Proteins
Collaboration focused on two targeted protein degraders from c4t's internal discovery pipeline c4t to receive a $16 million upfront payment; merck kgaa, darmstadt, germany, to cover discovery research costs under the collaboratio n c4t eligible for up to approximately $740 million in discovery, development and commercial milestone payments, in addition to future royalties, across entire collaboration watertown, mass., march 04, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced it has entered into a license and collaboration agreement with merck kgaa, darmstadt, germany, which operates its healthcare business as emd serono in the u...
2024-02-22 07:00:00 - Press Release
C4 Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Recent Business Highlights
Cft1946 preclinical data accepted for a poster presentation at the aacr annual meeting 2024 phase 1 dose escalation trials for cft7455 and cft1946 continue to progress; data from both trials expected in 2h 2024 well capitalized with cash runway expected into 2027 watertown, mass., feb. 22, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended december 31, 2023, as well as recent business updates.
Latest News
2024-03-05 16:30:00 - GlobeNewsWire
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis
2024-02-22 09:15:30 - Zacks Investment Research
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.76 per share a year ago.
2024-02-15 11:21:05 - Zacks Investment Research
C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?
When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
2024-02-15 11:06:54 - Zacks Investment Research
C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
C4 Therapeutics, Inc. (CCCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-01-09 19:34:20 - Zacks Investment Research
C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden Cross
From a technical perspective, C4 Therapeutics, Inc. (CCCC) is looking like an interesting pick, as it just reached a key level of support. CCCC's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
2024-01-03 12:47:58 - Zacks Investment Research
C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why
C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.
2023-12-27 12:47:23 - Zacks Investment Research
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.
2023-12-18 08:58:22 - MarketBeat
C4 Therapeutics blasts off: what's next?
As the market soars to new heights, with capital fast flowing back into the small-cap, more speculative, and traditionally risky investments and sectors, C4 Therapeutics NASDAQ: CCCC has become the latest small-cap stock to surge higher in price.
2023-12-13 14:17:42 - Zacks Investment Research
C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck
C4 Therapeutics (CCCC) inks an agreement with Merck to discover and develop degrader-antibody conjugates with a focus on one oncology target. Shares rise on the same.
2023-12-13 06:51:00 - Market Watch
Throw away those target-date funds, and don't hold bonds at all, says this daring new research
The last Fed meeting of the year is upon us, as those record highs for stock markets just keep coming. Can the Fed keep those fires burning?